Thesis

86 Chapter 4 Table 1. Demographics N available Total Stable N=337 (84%) Progression N=64 (16%) Age1 401 60.9±8.5a,b 60±8.4 66±7.3 Sex, female2 401 167 (42%) 141 (42%) 26 (41%) Education3 398 6[5-6] 6[5-6] 6[4-6] MMSE3 399 28.3±1.6a,b 28.4±1.5 27.8±1.6 APOE ε4 carriership2 388 153 (39%)a,b 115 (35%) 38 (61%) Hypertension2 401 78 (19%) 67 (20%) 11 (17%) Hypercholesterolemia2 401 34 (8.5%) 30 (8.9%) 4 (6.2%) Diabetes Mellitus4 401 31 (7.7%) 30 (8.9%) 1 (1.6%) BMI > 302 317 42 (13%) 37 (14%) 5 (10%) CSF Aβ1 401 1031.5±259.5a,b 1072.2±238 817.0±264.4 CSF p-tau3 401 49.9±24.2a,b 46.5±20.2 67.8±33.8 CSF t-tau3 401 313.7±223.2a,b 278.1±165.1 501±358.4 MTA score3 364 0[0-0.5]a 0[0-0.5] 0[0-1] N available (%) 305 (90.5%) 59 (92.2%) HV1 361 4.7±0.6a,b 4.8±0.6 4.5±0.5 N available (%) 303 (89.9%) 58 (90.6%) Serum NfL3 296 10.9±5.8a,b 10.2±5.6 14.3±5.7 N available (%) 245 (72.7%) 51 (79.7%) Serum GFAP3 296 206.4±129.9a,b 190.8±124.9 281.1±128.6 N available (%) 245 (72.7%) 51 (79.7%) Total follow-up time3 401 3.8±2.8a,b 3.6±2.7 4.5±3.2 Time to diagnosis 64 3.0±2.9 Number of visits3 399 3[2-4]a,b 2[2-3] 4[3-6] Abbreviations: Aβ = β-amyloid; BMI = body mass index; GFAP = glial fibrillary acidic protein; HV = hippocampal volume; MMSE = mini-mental state examination; MTA = medial temporal atrophy; NfL = neurofilament light; p-tau = phosphorylated tau; t-tau = total tau. Values are mean ± SD, n (%) or median [interquartile range]. Individuals were classified in the ‘Progression’ group if they showed clinical progression to mild cognitive impairment or dementia during follow-up. MRI was available for n=366. There were some missing values for MTA score (n=364) and HV (n=361) due to registration and segmentation errors. 1 t-test, 2 chi-square test, 3 Mann-Whitney U test, 4 Fisher’s exact test, a p <0.05, b False discovery rate-corrected p <0.05

RkJQdWJsaXNoZXIy MjY0ODMw